Safety of oral dronabinol during opioid withdrawal in humans
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background Opioid dependence remains a significant public health problem worldwide with only three FDA-approved treatments, all targeting the mu-opioid receptor. Dronabinol, a cannabinoid (CB) 1 receptor agonist, is currently under investigation as a novel opioid withdrawal treatment. This study reports on safety outcomes of dronabinol among adults in opioid withdrawal. Methods Twelve adults physically dependent on short-acting opioids participated in this 5-week within-subject, randomized, double blind, placebo-controlled inpatient study. Volunteers were maintained on oral oxycodone 30mg qid. Double-blind placebo substitutions occurred for 21 hours before each of 7 experimental sessions in order to produce opioid withdrawal. A single oral test dose was administered each session (placebo, oxycodone 30 and 60mg, dronabinol 5, 10, 20, and 30mg [decreased from 40mg]). Heart rate, blood pressure, respiratory outcomes and pupil diameter were assessed repeatedly. Results Dronabinol 40mg produced sustained sinus tachycardia accompanied by anxiety and panic necessitating dose reduction to 30mg. Sinus tachycardia and anxiety also occurred in one volunteer after dronabinol 20mg. Compared to placebo, dronabinol 20 and 30mg produced significant increases in heart rate beginning 1 hour after drug administration that lasted approximately two hours (p<0.05). Dronabinol 5 and 10mg produced placebo-like effects. Oxycodone produced prototypic mu-opioid agonist effects (e.g., miosis). Conclusion Dronabinol 20mg and higher increased heart rate among healthy adults at rest who were in a state of opioid withdrawal, raising concern about its safety. These results have important implications for future dosing strategies and may limit the utility of dronabinol as a treatment for opioid withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats
Navarro, M., Chowen, J., Carrera, M. R. A., del Arco, I., Villanúa, M. A., Martin, Y., Roberts, A. J., Koob, G. F., & de Fonseca, F. R. (1998) · NeuroReport · doi:10.1097/00001756-199810260-00012 · Cited by 152 · cited 2×
“Preclinical studies have reported that CB1 agonists (i.e., Δ9-THC) attenuate signs of opioid withdrawal (Lichtman et al 2001; Cichewicz and Welch 2003), while conversely; CB1 antagonists (SR 141716A) elicit opioid withdrawal signs (Navarro et al., 1998).”
BackgroundCichewicz, D. L., & Welch, S. P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046870 · Cited by 110 · cited 1×
“Preclinical studies have reported that CB1 agonists (i.e., Δ9-THC) attenuate signs of opioid withdrawal (Lichtman et al 2001; Cichewicz and Welch 2003), while conversely; CB1 antagonists (SR 141716A) elicit opioid withdrawal signs (Navarro et al., 1998).”
BackgroundBedi, G., Cooper, Z. D., & Haney, M. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00427.x · Cited by 83
Cited by
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
De Aquino, J. P., Sofuoglu, M., Stefanovics, E. A., & Rosenheck, R. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1818248 · Cited by 6
Metadata
- Authors
- Jicha, C. J., Lofwall, M. R., Nuzzo, P. A., Babalonis, S., Elayi, S. C., & Walsh, S. L.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 157
- Pages
- 179-183
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W1875095310
- Cited by
- 49
- References
- 3
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of oral dronabinol during opioid withdrawal in humans. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2015.09.031
- The paper
- Jicha, C. J., Lofwall, M. R., Nuzzo, P. A., Babalonis, S., Elayi, S. C., & Walsh, S. L. (2015). Safety of oral dronabinol during opioid withdrawal in humans. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2015.09.031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.